A Bayesian population PBPK model for multiroute chloroform exposure

Journal of Exposure Science and Environmental Epidemiology

Volumn 20, Issue 4, 2010, Pages 326-341

  Yang, Yuching ^a,b   Xu, Xu ^a,c   Georgopoulos, Panos G ^a  

^a RUTGERS UNIVERSITY   (United States)

^b HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROFORM;

ADULT; AIR POLLUTANT; ARTICLE; BATH; BAYES THEOREM; BIOLOGICAL MODEL; EXPOSURE; FEMALE; HEAT; HUMAN; MALE; PHYSIOLOGY; RISK ASSESSMENT; SKIN ABSORPTION;

ADULT; AIR POLLUTANTS; BATHS; BAYES THEOREM; CHLOROFORM; FEMALE; HOT TEMPERATURE; HUMANS; INHALATION EXPOSURE; MALE; MODELS, BIOLOGICAL; RISK ASSESSMENT; SKIN ABSORPTION;

EID: 77952672752     PISSN: 15590631     EISSN: 1559064X     Source Type: Journal    
DOI: 10.1038/jes.2009.29     Document Type: Article

References (68)

1. AEgis Technologies. acslX Modeling and Simulation Software 2008: http:// www.acslsim.com/.
2. Ainsworth B.E. The Compendium of Physical Activities Tracking Guide, Prevention Research Center, Norman J. Arnold School of Public Health, University of South Carolina 2002: http://prevention.sph.sc.edu/tools/docs/documents- compendium.pdf.
3. Allison T.G., Maresh C.M., and Armstrong L.E. Cardiovascular responses in a whirlpool bath at 40 degrees C versus user-controlled water temperatures. Mayo Clin Proc 1998: 73(3): 210-215.
4. Allison T.G., and Reger W.E. Comparison of responses of men to immersion in circulating water at 40.0 and 41.5 degrees C. Aviat Space Environ Med 1998: 69(9): 845-850.
5. Andersen M.E. Toxicokinetic modeling and its applications in chemical risk assessment. Toxicol Lett 2003: 138(1-2): 9-27.
6. ATSDR. Toxicological profile for chloroform, U.S. Department of Health and Human Services, Agency for Toxic Substances and Disease Registry 1997: http://www.atsdr.cdc.gov/toxprofiles/tp6.pdf.
7. Barash P., Cullen B., and Stoelting R. Handbook of Clinical Anesthesia. Lippincott Williams and Wilkins, USA, 2000.
8. Bernillon P., and Bois F.Y. Statistical issues in toxicokinetic modeling: a Bayesian perspective. Environ Health Perspect 2000: 108(Suppl 5): 883-893.
9. Bogaards J.J., van Ommen B., and van Bladeren P.J. Interindividual differences in the in vitro conjugation of methylene chloride with glutathione by cytosolic glutathione S-transferase in 22 human liver samples. Biochem Pharmacol 1993: 45(10): 2166-2169.
10. Bois F.Y. Analysis of PBPK models for risk characterization. Ann NY Acad Sci 1999: 895: 317-337.
11. Bois F.Y. Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics. Environ Health Perspect 2000a: 108(Suppl 2): 307-316.
12. Bois F.Y. Statistical analysis of Fisher et al. PBPK model of trichloroethylene kinetics. Environ Health Perspect 2000b: 108(Suppl 2): 275-282.
13. Bois F.Y., Gelman A., Jiang J., Maszle D.R., Zeise L., and Alexeef G. Population toxicokinetics of tetrachloroethylene. Arch Toxicol 1996a: 70(6): 347-355.
14. Bois F.Y., Jackson E.T., Pekari K., and Smith M.T. Population toxicokinetics of benzene. Environ Health Perspect 1996b: 104(Suppl 6): 1405-1411.
15. Bois F.Y., Smith T.J., Gelman A., Chang H.Y., and Smith A.E. Optimal design for a study of butadiene toxicokinetics in humans. Toxicol Sci 1999: 49(2): 213-224.
16. Bolt H.M., Roos P.H., and Their R. The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine. Int Arch Occup Environ Health 2003: 76(3): 174-185.
17. Boone T., Westendorf T., and Ayres P. Cardiovascular responses to a hot tub bath. J Altern Complement Med 1999: 5(3): 301-304.
18. Bortot P., Thomaseth K., and Salvan A. Population toxicokinetic analysis of 2,3,7,8-tetrachlorodibenzo-p-dioxin using Bayesian techniques. Stat Med 2002: 21(4): 533-547.
19. Brooks S.P., and Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 1998: 7: 434-455.
20. Charkoudian N. Skin blood flow in adult human thermoregulation: how it works, when it does not, and why. Mayo Clin Proc 2003: 78(5): 603-612.
21. Clewell H.J., Gentry P.R., Covington T.R., and Gearhart J.M. Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. Environ Health Perspect 2000: 108: 283-305.
22. Clewell H.J., Gentry P.R., Kester J.E., and Andersen M.E. Evaluation of physiologically based pharmacokinetic models in risk assessment: an example with perchloroethylene. Crit Rev Toxicol 2005: 35(5): 413-433.
23. Clewell H.J., Lee T.S., and Carpenter R.L. Sensitivity of physiologically-based pharmacokinetic models to variation in model parametersFmethylenechloride. Risk Anal 1994: 14(4): 521-531.
24. Clewell H.J., Tan Y.M., Campbell J.L., and Andersen M.E. Quantitative interpretation of human biomonitoring data. Toxicol Appl Pharmacol 2008: 231(1): 122-133.
25. Clewell R.A., Merrill E.A., Yu K.O., Mahle D.A., Sterner T.R., Mattie D.R., Robinson P.J., Fisher J.W., and Gearhart J.M. Predicting fetal perchlorate dose and inhibition of iodide kinetics during gestation: a physiologically- based pharmacokinetic analysis of perchlorate and iodide kinetics in the rat. Toxicol Sci 2003: 73(2): 235-255.
26. Corley R.A., Gordon S.M., and Wallace L.A. Physiologically based pharmacokinetic modeling of the temperature-dependent dermal absorption of chloroform by humans following bath water exposures. Toxicol Sci 2000: 53(1): 13-23.
27. Corley R.A., Mendrala A.L., Smith F.A., Staats D.A., Gargas M.L., Conolly R.B., AndersenM.E., and Reitz R.H. Development of a physiologically based pharmacokinetic model for chloroform. Toxicol Appl Pharmacol 1990: 103(3): 512-527.
28. Gallegos A.F., andWenzelW.J. HUMTRN: Documentation and Verification for an ICRP-Based Age- and Sex-Specific Human Simulation Model for Radionuclide Dose Assessment. Los Alamos National Laboratory, Los Alamos, NM, 1984.
29. Gelman A., Bois F., and Jiang J.M. Physiological pharmacokinetic analysis using population modeling and informative prior distributions. J Am Stat Assoc 1996: 91(436): 1400-1412.
30. Georgopoulos P.G., Wang S.W., Vyas V.M., Sun Q., Burke J., Vedantham R., McCurdy T., and Ozkaynak H. A source-to-dose assessment of population exposures to fine PM and ozone in Philadelphia, PA, during a summer 1999 episode. J Expo Anal Environ Epidemiol 2005: 15(5): 439-457.
31. Gibb H.J., Checkoway H., and Stayner L. Improving risk assessment: priorities for epidemiologic research. Human Ecol Risk Assess 2002: 8: 1397-1404.
32. Gordon S.M., Wallace L.A., Callahan P.J., Kenny D.V., and Brinkman M.C. Effect of water temperature on dermal exposure to chloroform. Environ Health Perspect 1998: 106(6): 337-345.
33. Hack C.E., Chiu W.A., Jay Zhao Q., and Clewell H.J. Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites. Regul Toxicol Pharmacol 2006: 46(1): 63-83.
34. Haddad S., Tardif G.C., and Tardif R. Development of physiologically based toxicokinetic models for improving the human indoor exposure assessment to water contaminants: trichloroethylene and trihalomethanes. J Toxicol Environ Health A 2006: 69(23): 2095-2136.
35. ICRP. Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89. Ann ICRP 2002: 32(3-4): 5-265.
36. ILSI. An evaluation of EPA's proposed guidelines for carcinogen risk assessment using chloroform and dichloroacetate as case studies: report of an expert panel. International Life Sciences Institute, Washington, DC, 1997.
37. Jo W.K., Weisel C.P., and Lioy P.J. Routes of chloroform exposure and body burden from showering with chlorinated tap water. Risk Anal 1990: 10(4): 575-580.
38. Johanson G., and Naslund P.H. Spreadsheet programming-a new approach in physiologically based modeling of solvent toxicokinetics. Toxicol Lett 1988: 41(2): 115-127.
39. Jonsson F., Bois F., and Johanson G. Physiologically based pharmacokinetic modeling of inhalation exposure of humans to dichloromethane during moderate to heavy exercise. Toxicol Sci 2001: 59(2): 209-218. (Pubitemid 32149551)
40. Jonsson F., and Johanson G. Bayesian estimation of variability in adipose tissue blood flow in man by physiologically based pharmacokinetic modeling of inhalation exposure to toluene. Toxicology 2001: 157(3): 177-193.
41. Kanter G.S. Glomerular filtration and renal plasma flow during hyperthermia. Am J Physiol 1960: 198: 1044-1048.
42. Kenney M., and Musch T. Senescence alters blood flow responses to acute heat stress. Am J Physiol Heart Circ Physiol 2004: 286: 1480-1485.
43. Kim R.B., Yamazaki H., Chiba K., O'Shea D., Mimura M., Guengerich F.P., Ishizaki T., Shimada T., and Wilkinson G.R. In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. J Pharmacol Exp Ther 1996: 279(1): 4-11.
44. Koda M., Komori S., Nagami M., Minohara M., Murawaki Y., Horie Y., Suou T., Kawasaki H., and Ikawa S. Effects of bathing in hot water on portal hemodynamics in healthy subjects and in patients with compensated liver cirrhosis. Intern Med 1995: 34(7): 628-631.
45. Layton D.W. Metabolically consistent breathing rates for use in dose assessments. Health Phys 1993: 64(1): 23-36.
46. Levesque B., Ayotte P., Tardif R., Charest-Tardif G., Dewailly E., Prud'Homme D., Gingras G., Allaire S., and Lavoie R. Evaluation of the health risk associated with exposure to chloroform in indoor swimming pools. J Toxicol Environ Health A 2000: 61(4): 225-243.
47. Liao K.H., Tan Y.M., Conolly R.B., Borghoff S.J., Gargas M.L., Andersen M.E., and Clewell III H.J. Bayesian estimation of pharmacokinetic and pharmacodynamic parameters in a mode-of-action-based cancer risk assessment for chloroform. Risk Anal 2007: 27(6): 1535-1551.
48. Louis T.A. Assessing, accommodating, and interpreting the influences of heterogeneity. Environ Health Perspect 1991: 90: 215-222.
49. Marino D.J., Clewell H.J., Gentry P.R., Covington T.R., Hack C.E., David R.M., and Morgott D.A. Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice. Regul Toxicol Pharmacol 2006: 45(1): 44-54.
50. Miwa C., Matsukawa T., Iwase S., Sugiyama Y., Mano T., Sugenoya J., Yamaguchi H., and Kirsch K.A. Human cardiovascular responses to a 60-min bath at 40 degrees C. Environ Med 1994: 38(1): 77-80.
51. Nakai J.S., Stathopulos P.B., Campbell G.L., Chu I., Li-Muller A., and Aucoin R. Penetration of chloroform, trichloroethylene, and tetrachloroethylene through human skin. J Toxicol Environ Health A 1999: 58(3): 157-170.
52. Nestorov I. Modeling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics. Toxicol Lett 2001: 120(1-3): 411-420.
53. Price P.S., Conolly R.B., Chaisson C.F., Gross E.A., Young J.S., Mathis E.T., and Tedder D.R. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol 2003: 33(5): 469-503.
54. Raucy J.L. Risk assessment: toxicity from chemical exposure resulting from enhanced expression of CYP2E1. Toxicology 1995: 105(2-3): 217-224.
55. Roy A., Weisel C., Lioy P.J., and Georgopoulos P.G. A distributed parameter physiologically based pharmacokinetic model for dermal and inhalation exposure to volatile organic compounds. Risk Anal 1996: 16: 147-160.
56. Sohn M.D., McKone T.E., and Blancato J.N. Reconstructing population exposures from dose biomarkers: inhalation of trichloroethylene (TCE) as a case study. J Expo Anal Environ Epidemiol 2004: 14(3): 204-213.
57. Song C.W., Chelstrom L.M., and Haumschild D.J. Changes in human skin blood flow by hyperthermia. Int J Radiat Oncol Biol Phys 1990: 18(4): 903-907.
58. Steiner E.C., Rey T.D., and McCroskey P.S. Reference Guide for Simusolv. The Dow Chemical Company, Midland, MI, 1990.
59. Tan Y.M., Liao K.H., Conolly R.B., Blount B.C., Mason A.M., and Clewell H.J. Use of a physiologically based pharmacokinetic model to identify exposures consistent with human biomonitoring data for chloroform. J Toxicol Environ Health A 2006: 69(18): 1727-1756.
60. The Mathworks Inc. Matlab and Simulink Technical Computing. 2008: http:// www.mathworks.com/.
61. USEPA. Dermal Exposure Assessment: Principles and Application. EPA/600/8-91/ 011B, USEPA Office of Health and Environmental Assessment 1992: http:// www.epa.gov/ncea/pdfs/efh/references/DEREXP.PDF.
62. USEPA. Exposure Factors Handbook. EPA/600/C-99/001, US Environmental Protection Agency 1997: http://www.epa.gov/ncea/pdfs/efh/efh-complete.pdf.
63. Wallace L.A. Human exposure and body burden for chloroform and other trihalomethanes. Crit Rev Environ Sci Technol 1997: 27: 113-194.
64. Wilkes C.R., Small M.J., Davidson C.I., and Andelman J.B. Modeling the effects of water usage and co-behavior on inhalation exposures to contaminants volatilized from household water. J Expo Anal Environ Epidemiol 1996: 6(4): 393-412.
65. Xu X., Mariano T.M., Laskin J.D., and Weisel C.P. Percutaneous absorption of trihalomethanes, haloacetic acids, and haloketones. Toxicol Appl Pharmacol 2002: 184(1): 19-26.
66. Xu X., and Weisel C.P. Dermal uptake of chloroform and haloketones during bathing. J Expo Anal Environ Epidemiol 2005a: 15(4): 289-296. (Pubitemid 41140902)
67. Xu X., and Weisel C.P. Human respiratory uptake of chloroform and haloketones during showering. J Expo Anal Environ Epidemiol 2005b: 15(1): 6-16. (Pubitemid 40170979)
68. Zeise L., Hattis D., Andersen M., Bailer A.J., Bayard S., Chen C., Clewell H., Conolly R., Crump K., Dunson D., Finkel A., Haber L., Jarabek A., Kodell R., Krewski D., Thomas D., Thorslund T., and Wassell J.T. Improving risk assessment: research opportunities in dose response modeling to improve risk assessment. Human Ecol Risk Assess 2002: 8: 1424-1444.